Category: Manufacturer
Manufacturer
Steris Corp. débuts a system to integrate operating room imaging technologies on a single touchscreen at the Assn. of periOperative Registered Nurses meeting in Denver.
By Mary Vanac
Mentor, Ohio-based Steris Corp. (NYSE:STE) launched a system that integrates operating room visualization technologies on a single touch-screen.
Introduced at the Assn. of periOperative Registered Nurses Congress in Denver, the Harmony iQ 2100 Integration System is a joint venture produced in tandem with VTS Medical Systems LLC of Melville, N.Y. It takes several units that control cameras, imaging devices and navigation equipment off a stacked tower or rack and consolidates them on one computer screen and microprocessor.
The Food & Drug Administration orders a Class I recall of Abiomed's AB5000 heart support device, after receiving reports of computer problems causing it to lose power.
Abiomed Inc. (NSDQ:ABIO) was hit with a Class I recall of its AB5000 Circulatory Support System after receiving reports that the computer supplying power to the company's disposable heart pumps may shut down without warning.
Class 1 recalls are the most serious type of recall and involve situations in which there is a reasonable probability that use of these products could cause serious injury or death.
Ernie Whiton, CFO at Zoll Medical Corp., announces plans to sell up to 90,000 shares of company stock over the next year.
Ernie Whiton is not a person who lets stock options lay around without getting some exercise.
The CFO at Zoll Medical Corp. (NSDQ:ZOLL) is preparing to sell off another large slice of his company stock, disclosing plans this week to offer up to 90,000 shares through a series of pre-arranged sales beginning next month.
Whiton joined the Chelmsford, Mass.-based maker of defibrillators in January 1999, following a six-year stint at Ionics Inc. (now part of General Electric) in Watertown, Mass. He earns $280,000 in annual salary and holds a total of 107,750 vested options to buy Zoll stock priced between $11.26 and $23.05 a share, awarded through Zoll's long-term equity incentive compensation plan.
Tenex Health Inc., led by former Boston Scientific executive Jagi Gill, raises $1.3 million in an equity sale.
By Thomas Lee
Tenex Health Inc. raised $1.3 million from the sale of equity, according to a filing with the Securities & Exchange Commission.
The Rochester, Minn.-based biotech start-up, which is seeking a total of $2 million, is developing treatments for sports-related injuries such as tendinitis.
Founder and CEO Jagi Gill did not return a phone call seeking comment.
It's never to early in the life of a startup to explore potential partnerships. Just ask CardioInsight CEO Steve Arless, whose decision as leader of CryoCath Technologies to pass up a $50 million deal with Johnson & Johnson meant years of fund-raising and public offerings.
By Mary Vanac
Steve Arless learned the hard way that it’s never too early to start talking to potential commercial partners who could help develop your early-stage medical technology company.
Arless told an Ohio Venture Association group March 12 that his decision to pass on an early commercial development offer ended up costing his company a lot more money.
The biggest names in medical devices, including Boston Scientific, Abbott and Medtronic, tout data from studies of their cardiovascular devices at the American College of Cardiology's 59th annual scientific session in Atlanta.
The biggest names in the medical device world are busy touting the results of several clinical trials of their cardiovascular products, with more to come from the American College of Cardiology's 59th annual scientific session.
Companies including Boston Scientific Corp. (NYSE:BSX), Johnson & Johnson (NYSE:JNJ), Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) are making presentation after presentation at the Atlanta conference, hoping to drum up abuzz among the attending surgeons.
Boston Scientific touts Taxus Express, Element data
Scientists at Yale University believe they have discovered the signaling mechanism at work during artery formation, opening up the possibility of growing replacement arteries; Rex Medical's thrombectomy system wins FDA nod; Cook's NavAlign IVC filter placement system gets femoral access option; and STJ's new Engage and Engage TR catheter introducers.
Signaling pathways foreshadow novel vascular therapies: Scientists at Yale University believe they have discovered the signaling mechanism at work during artery formation, which may end up being used to control the growth of replacement arteries for people with coronary stenoses and other vascular ailments. Until now, scientists have focused on growth factors as tools to control vessel formation, but the new research provides a direct signaling mechanism that's already proving to be more effective.
